CORBUS PHARMACEUTICALS HOLDI (CRBP) Stock Fundamental Analysis

NASDAQ:CRBP • US21833P3010

7.68 USD
+0.27 (+3.64%)
At close: Feb 19, 2026
7.53 USD
-0.15 (-1.95%)
After Hours: 2/19/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, CRBP scores 2 out of 10 in our fundamental rating. CRBP was compared to 521 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CRBP as it has an excellent financial health rating, but there are worries on the profitability. CRBP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CRBP has reported negative net income.
  • In the past year CRBP has reported a negative cash flow from operations.
  • CRBP had negative earnings in each of the past 5 years.
  • CRBP had a negative operating cash flow in each of the past 5 years.
CRBP Yearly Net Income VS EBIT VS OCF VS FCFCRBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of CRBP (-61.65%) is comparable to the rest of the industry.
  • CRBP's Return On Equity of -73.27% is in line compared to the rest of the industry. CRBP outperforms 54.89% of its industry peers.
Industry RankSector Rank
ROA -61.65%
ROE -73.27%
ROIC N/A
ROA(3y)-82.9%
ROA(5y)-79.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRBP Yearly ROA, ROE, ROICCRBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CRBP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRBP Yearly Profit, Operating, Gross MarginsCRBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The number of shares outstanding for CRBP has been increased compared to 1 year ago.
  • CRBP has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for CRBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRBP Yearly Shares OutstandingCRBP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CRBP Yearly Total Debt VS Total AssetsCRBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -3.48, we must say that CRBP is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -3.48, CRBP is in line with its industry, outperforming 44.91% of the companies in the same industry.
  • CRBP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.48
ROIC/WACCN/A
WACCN/A
CRBP Yearly LT Debt VS Equity VS FCFCRBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

  • CRBP has a Current Ratio of 6.31. This indicates that CRBP is financially healthy and has no problem in meeting its short term obligations.
  • CRBP's Current ratio of 6.31 is fine compared to the rest of the industry. CRBP outperforms 64.68% of its industry peers.
  • A Quick Ratio of 6.31 indicates that CRBP has no problem at all paying its short term obligations.
  • CRBP's Quick ratio of 6.31 is fine compared to the rest of the industry. CRBP outperforms 65.64% of its industry peers.
Industry RankSector Rank
Current Ratio 6.31
Quick Ratio 6.31
CRBP Yearly Current Assets VS Current LiabilitesCRBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • CRBP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.48%.
EPS 1Y (TTM)-17.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -9.22% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-89.66%
EPS Next 2Y-19.62%
EPS Next 3Y-15.13%
EPS Next 5Y-9.22%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRBP Yearly Revenue VS EstimatesCRBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
CRBP Yearly EPS VS EstimatesCRBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -20 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CRBP. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRBP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRBP Price Earnings VS Forward Price EarningsCRBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRBP Per share dataCRBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

  • CRBP's earnings are expected to decrease with -15.13% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.62%
EPS Next 3Y-15.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CRBP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CORBUS PHARMACEUTICALS HOLDI

NASDAQ:CRBP (2/19/2026, 8:00:01 PM)

After market: 7.53 -0.15 (-1.95%)

7.68

+0.27 (+3.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-09
Inst Owners49.72%
Inst Owner Change25.96%
Ins Owners0.36%
Ins Owner Change1.86%
Market Cap134.78M
Revenue(TTM)N/A
Net Income(TTM)-67.51M
Analysts86.25
Price Target43.18 (462.24%)
Short Float %8.28%
Short Ratio4.51
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.24%
Min EPS beat(2)-9.1%
Max EPS beat(2)6.63%
EPS beat(4)2
Avg EPS beat(4)7.66%
Min EPS beat(4)-9.1%
Max EPS beat(4)39.57%
EPS beat(8)5
Avg EPS beat(8)11.01%
EPS beat(12)7
Avg EPS beat(12)8.52%
EPS beat(16)9
Avg EPS beat(16)2.23%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.15%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)33.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.46
P/tB 1.46
EV/EBITDA N/A
EPS(TTM)-5.51
EYN/A
EPS(NY)-5.24
Fwd EYN/A
FCF(TTM)-3.39
FCFYN/A
OCF(TTM)-3.39
OCFYN/A
SpS0
BVpS5.25
TBVpS5.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -61.65%
ROE -73.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-82.9%
ROA(5y)-79.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.31
Quick Ratio 6.31
Altman-Z -3.48
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65.22%
EPS Next Y-89.66%
EPS Next 2Y-19.62%
EPS Next 3Y-15.13%
EPS Next 5Y-9.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-64.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3Y-19.79%
EBIT Next 5Y-22.09%
FCF growth 1Y-58.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.53%
OCF growth 3YN/A
OCF growth 5YN/A

CORBUS PHARMACEUTICALS HOLDI / CRBP FAQ

What is the ChartMill fundamental rating of CORBUS PHARMACEUTICALS HOLDI (CRBP) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CRBP.


Can you provide the valuation status for CORBUS PHARMACEUTICALS HOLDI?

ChartMill assigns a valuation rating of 0 / 10 to CORBUS PHARMACEUTICALS HOLDI (CRBP). This can be considered as Overvalued.


Can you provide the profitability details for CORBUS PHARMACEUTICALS HOLDI?

CORBUS PHARMACEUTICALS HOLDI (CRBP) has a profitability rating of 1 / 10.


Can you provide the financial health for CRBP stock?

The financial health rating of CORBUS PHARMACEUTICALS HOLDI (CRBP) is 7 / 10.


Can you provide the expected EPS growth for CRBP stock?

The Earnings per Share (EPS) of CORBUS PHARMACEUTICALS HOLDI (CRBP) is expected to decline by -89.66% in the next year.